- Home
- EMO vs CDXC Comparison
EMO vs CDXC Comparison
Compare EMO & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- CDXC
- Stock Information
- Founded
- EMO 2011
- CDXC 1999
- Country
- EMO United States
- CDXC United States
- Employees
- EMO N/A
- CDXC N/A
- Industry
- EMO Investment Managers
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- EMO Finance
- CDXC Health Care
- Exchange
- EMO Nasdaq
- CDXC Nasdaq
- Market Cap
- EMO 547.7M
- CDXC 546.9M
- IPO Year
- EMO N/A
- CDXC N/A
- Fundamental
- Price
- EMO $47.75
- CDXC $6.82
- Analyst Decision
- EMO
- CDXC Strong Buy
- Analyst Count
- EMO 0
- CDXC 2
- Target Price
- EMO N/A
- CDXC $8.00
- AVG Volume (30 Days)
- EMO 27.1K
- CDXC 2.8M
- Earning Date
- EMO 01-01-0001
- CDXC 10-31-2024
- Dividend Yield
- EMO 6.70%
- CDXC N/A
- EPS Growth
- EMO N/A
- CDXC N/A
- EPS
- EMO N/A
- CDXC 0.02
- Revenue
- EMO N/A
- CDXC $91,668,000.00
- Revenue This Year
- EMO N/A
- CDXC $18.64
- Revenue Next Year
- EMO N/A
- CDXC $20.72
- P/E Ratio
- EMO N/A
- CDXC $351.56
- Revenue Growth
- EMO N/A
- CDXC 9.95
- 52 Week Low
- EMO $26.42
- CDXC $1.32
- 52 Week High
- EMO $40.17
- CDXC $7.58
- Technical
- Relative Strength Index (RSI)
- EMO 76.75
- CDXC 70.03
- Support Level
- EMO $46.50
- CDXC $6.22
- Resistance Level
- EMO $47.40
- CDXC $7.58
- Average True Range (ATR)
- EMO 0.86
- CDXC 0.63
- MACD
- EMO 0.27
- CDXC 0.17
- Stochastic Oscillator
- EMO 97.09
- CDXC 81.42
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.